Q3 2025 net product revenue increased 223% year-over-year to $438,000. The company posted a gross loss of approximately $100,000 in the third quarter of 2025, compared to an approximate gross profit of $24,000 in the third quarter of 2024, due to a one-time inventory write-off associated with newly produced validation lots which will no longer be accepted by supply chain partners after the end of Q1 2026 due to limited remaining shelf-life. Additional lots with four-year shelf-life are currently in production and expected to fully enter the supply chain in early Q1 2026, the company stated.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- SXTP Upcoming Earnings Report: What to Expect?
- 60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis
- 60 Degrees announces first patient completed regimen in babesiosis trial
- 60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting
- 60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial